BMD is listed on Nasdaq and received positive feedback from the FDA regarding its Phase 3 drug protocol.
1 report, 1 independent
Updated Jun 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BMD is listed on Nasdaq and received positive feedback from the FDA regarding its Phase 3 drug protocol.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.
- Rocket is utilizing Nasdaq for investor evaluation and the FDA reviewed Phase 2 efficacy data for its product RP-A501.
- BMJ examined the FDA's flawed safety system, involving the FDA and Control Data Corporation.